Tandem Diabetes Care (TNDM) Receiving Somewhat Positive Media Coverage, Study Finds

Media coverage about Tandem Diabetes Care (NASDAQ:TNDM) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.7928585698559 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have effected Accern’s scoring:

Tandem Diabetes Care (TNDM) traded up $0.02 during trading hours on Friday, hitting $2.43. 739,278 shares of the company were exchanged, compared to its average volume of 1,030,000. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The company has a market cap of $24.59, a PE ratio of -0.12 and a beta of 0.44. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $26.00.

A number of brokerages have recently weighed in on TNDM. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Saturday, January 6th. Robert W. Baird restated a “hold” rating and issued a $3.00 target price on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $11.29.

In related news, Director Christopher J. Twomey purchased 75,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were bought at an average price of $2.00 per share, with a total value of $150,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kim D. Blickenstaff purchased 750,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $1,500,000.00. The disclosure for this purchase can be found here. Insiders own 20.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/18/tandem-diabetes-care-tndm-receiving-somewhat-positive-media-coverage-study-finds.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit